

Special Issue

Safety and Effectiveness of COVID-19 Vaccines on COVID-19 Infection and Its Long-Term Consequences

Message from the Guest Editor

The COVID-19 pandemic resulted in several health and financial problems, and the relevant vaccines urgently developed during this crisis were able to reduce the number of deaths and disease burdens. The persistence of COVID-19 infection after vaccination encourages the possibility of new vaccines to be used as booster strategies for new SARS-COV-2 variants. Additionally, it is important to unveil if current vaccines are able to avoid the long-term consequences of COVID-19 infection. Thus, this Special Issue will focus on the safety and effectiveness of COVID-19 vaccines in COVID-19 infection and their long-term consequences. Topics that can be explored include: new vaccines against COVID-19, the safety and efficacy of vaccines in clinical trials, and an analysis of the effects of vaccination on the COVID-19 recovery and the long-term infection consequences. We believe that sharing new knowledge on these subjects may lead to the better development of new vaccines or improve the current vaccines against COVID-19 to avoid the infection's long-term consequences.

Guest Editor

Dr. Ana Paula Junqueira-Kipnis

Department of Biosciences and Technology, Institute of Tropical Pathology and Public Health, Federal University of Goiás, Goiânia 74605-050, Brazil

Deadline for manuscript submissions

closed (31 December 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/133677

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).